Skip to content
DAN 50DAN 50DAN 50577757775777

Drawing based on the label description. No photo yet.

“Atenolol Tablets USP, 50 mg are 9/32", scored, round, white tablets imprinted DAN 50 and 5777”

DAN 50 5777 pill

Pill with imprint DAN 50 5777 is white, round, 9 mm and has been identified as Atenolol 50 mg. It is used for high blood pressure, heart failure and chest pain (angina). It is supplied by Rebel Distributors Corp.

Atenolol 50 mg

Imprint
DAN 50 5777
Strength
50 mg
Used for
High blood pressure, heart failure and chest pain (angina)
Color
White
Shape
Round
Size
9 mm
Score
Breaks into 2 pieces
Form
Tablet
Manufacturer
Rebel Distributors Corp
Drug class
Beta blocker (heart and blood pressure medicine)
NDC
21695-323, 0591-5777, 21695-323-30, 21695-323-60, 21695-323-90

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Atenolol pills and guides

What is Atenolol used for?

Atenolol is used for high blood pressure, heart failure, chest pain (angina) and atrial fibrillation (irregular heartbeat).

Medicine type
Beta blocker (heart and blood pressure medicine)
Official uses from the US prescribing label

Hypertension

Atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Atenolol tablets may be administered with other antihypertensive agents.

Angina Pectoris Due to Coronary Atherosclerosis

Atenolol tablets are indicated for the long-term management of patients with angina pectoris.

Acute Myocardial Infarction

Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows. (See DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS.) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit.

From the FDA-approved label on DailyMed (published Sep 29, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows DAN 50 5777. The parts can be split between the two sides, so turn the pill over and check both.
  • It is white, round, 9 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Atenolol

Inactive: Magnesium Carbonate, Magnesium Stearate, Silicon Dioxide, Sodium Lauryl Sulfate, Sodium Starch Glycolate Type A Potato, Starch, Corn

Other pills with imprint DAN 50 5777

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Atenolol pills